ResultsIQ

ResultsIQ › Latest results › Natural Capsules Limited

Natural Capsules Limited Q2 FY27 results deck summary

NSE: NATCAPSUQ · BSE: 524654

Results deck of 15 Nov 2026, summarised by AI from the filing.

Q2FY27 revenue ₹51.15 cr and EBITDA ₹3.01 cr as converted gelatine lines added volumes; EBITDA expected to stay in the current range.

Key takeaways

  1. Revenue Q2FY27 consolidated revenue from operations was ₹51.15 cr, up 5% Q-o-Q and 12% Y-o-Y.
  2. EBITDA outlook EBITDA is expected to remain in the current range over the coming quarters, with input costs possibly rising.
  3. Line conversion Idle HPMC lines were converted to gelatine, adding volumes; the second HPMC line is now being converted.
  4. Volume driver Gelatine volumes from the converted lines drove growth, with the prior quarter's around 3% realisation gain holding.
  5. API approvals API revenue build depends on WHO GMP certification and COPP filings, expected complete by March 2027.

Original filing on BSE

Natural Capsules Limited Q2 FY27 results

As filed: Revenue ₹51.2 cr (+11% year on year), EBITDA ₹3.0 cr, PAT −₹4.2 cr, EBITDA margin 5.9% (+808 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹48.7 cr (+8% year on year), EBITDA ₹1.1 cr (+12% year on year), PAT −₹5.7 cr, EBITDA margin 2.3% (+8 bps). Score 45 of 100, In line with trend. EBITDA margin was flat year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 17% from last quarter. Share price after the results: +19.1% in 30 days (Nifty 500: −3.4%).
  • Q4 FY26: Revenue ₹58.5 cr (+30% year on year), EBITDA ₹1.3 cr (−73% year on year), PAT −₹5.0 cr (−300% year on year), EBITDA margin 2.3% (−884 bps). Score 20 of 100, Below trend. EBITDA margin fell 884 bps year on year. Consolidated profit -598% but standalone +84%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −6.5% in 29 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹34.2 cr, EBITDA ₹1.9 cr, PAT ₹0.4 cr, EBITDA margin 5.5%. Not scored. No result for the same quarter last year. Share price after the results: −10.5% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹45.0 cr, EBITDA ₹5.0 cr, PAT ₹3.0 cr, EBITDA margin 11.1%. Not scored. No result for the same quarter last year. Share price after the results: −11.6% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹44.0 cr, EBITDA ₹4.0 cr, PAT ₹3.0 cr, EBITDA margin 9.1%. Not scored. No result for the same quarter last year. Share price after the results: −7.2% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹44.0 cr, EBITDA ₹5.0 cr, PAT ₹3.0 cr, EBITDA margin 11.4%. Not scored. No result for the same quarter last year. Share price after the results: −2.2% in 29 days (Nifty 500: +3.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Natural Capsules Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.